IHS Chemical Week

Regions :: Western Europe :: U.K.

DSM to Manufacture C. difficile Compound for U.K. Biotech Firm

12:16 AM MDT | June 11, 2010 | Deepti Ramesh

DSM BioSolutions, part of the DSM Pharma cluster, says it has entered into an agreement with biotechnology company Novacta Biosystems (Welwyn Garden City, U.K.) for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. Financial terms of the deal were not disclosed. DSM has completed the process development and has commenced cGMP-manufacturing of the Novacta compound at its microbial fermentation biotech facility at Capua, Italy.  The product will initially be used for pre-clinical and phase I...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa